What is most important when evaluating CGM?

A. Accurately evaluating glucose levels in the hypoglycemic range
B. Considering mean absolute relative differences in blood glucose (blood versus CGM value)
C. Considering patient-reported outcomes (positive experience and preference to or not to include CGM in their daily lives)
D. All of the above

Follow the link for the answer.

Is medication compliance a major issue with your patients? Follow the link to see what your colleagues say.

Jon S. Odorico, MD, FACS is Director of the Pancreas and Islet Cell Transplantation Programs and Professor in the Department of Surgery, Division of Organ Transplantation at the University of Wisconsin-Madison School of Medicine and Public Health.

In this week's Homerun Slides, understanding the sensor procedure for the Eversense CGM.

Identification of T2DM affecting genetic variants: The methods used to map disease-causing variation have evolved rapidly in the last decades thanks to technical advances in genotyping methods. Originally, disease-causing loci were identified primarily by linkage analysis, utilizing the long stretches of linkage in affected families. By genotyping 400–500 genetic markers, disease loci can be mapped on a genome-wide level without any prior hypothesis about which genes are involved. Finding that affected family members share a certain marker that is identical by descent (i.e., identical because it was inherited from the same parent) more often than expected by chance is evidence that a disease-causing variant is in linkage with that marker. This strategy has been very successful in mapping genetic diseases like MODY that have a strong penetrance and a known mode of inheritance.

In this Exclusive Interview transcript, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about advances in the work with stem cell derived beta cells.

In this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about advances in the work with beta cells.

In part 1 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about advances in the work on stem cell-derived beta cells.

In part 2 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the results of the Viactye trial as shared at a recent opinion leaders meeting.

In part 3 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about the remaining challenges in the work with stem cell-derived beta cells.